

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) A pharmaceutical composition for the treatment of skin neoplasm comprising a therapeutically effective amount of arsenic trioxide and a pharmaceutically acceptable carrier, wherein said composition is in the form of a cream, lotion, gel, ointment or paste.

2. (original) The pharmaceutical composition as claimed in claim 1, wherein the skin neoplasm is selected from the group consisting of subcutaneous tumors, primary skin cancer, melanomatous cancer and metastatic cutaneous cancer.

3. (withdrawn) The pharmaceutical composition as claimed in claim 2, wherein the primary skin cancer is selected from the group consisting of basic cell carcinoma, squamous cell carcinoma and Merkel cell carcinoma.

4. (canceled)

5. (withdrawn) A dosage form suitable for topical administration which comprises a composition as claimed in claim 3.

6. (withdrawn) The dosage form as claimed in claim 5, wherein the dosage form further comprises viscid substance.

7. (withdrawn) The dosage form as claimed in claim 6, wherein the viscid substance is starch or polymer.

8. (withdrawn) The dosage form as claimed in claim 7, wherein the polymer is polyarylic acid, carbomer, hydroxyethyl cellulose, chitosan, hydroxypropyl cellulose, hydroxypropyl methylcellulose, sodium carboxymethylcellulose, polyvinyl alcohol or a mixture thereof.

9. (withdrawn) The dosage form as claimed in claim 8 in the form of a gel.

10. (withdrawn) The dosage form as claimed in claim 9, wherein the gel comprises by weight based on the total weight of the gel 0.05% arsenic trioxide; 1.5% carbomer 940; 5.5% PEG; and 0.125% propyl paraben.

11. (withdrawn) A method of treating skin neoplasm in a human comprising administering to a human in need thereof a therapeutically effective amount of a pharmaceutical composition comprising arsenic trioxide.

12. (withdrawn) A method as claimed in claim 11, wherein the skin neoplasm is selected from the group consisting of subcutaneous tumors, primary skin cancer, melanomatous cancer and metastatic cutaneous cancer.

13. (withdrawn) A method as claimed in claim 12, wherein the primary skin cancer is selected from the group consisting of basic cell carcinoma, squamous cell carcinoma and Merkel cell carcinoma.

14. (withdrawn) A method as claimed in claim 13, wherein the composition is in the form of a cream, lotion, solution, gel, ointment or paste.

15. (withdrawn) A method as claimed in claim 14, wherein the composition is administered topically.

16. (withdrawn) A method as claimed in claim 15, wherein arsenic trioxide is present at about 0.01 to about 1 mg/g of the composition.

17. (withdrawn) A method as claimed in claim 15, wherein arsenic trioxide is present at about 0.1 to about 0.5 mg/g of the composition.

18. (new) A dosage form suitable for topical administration which comprises a composition as claimed in claim 1.

19. (new) The dosage form as claimed in claim 18, wherein the dosage form further comprises viscid substance.

20. (new) The dosage form as claimed in claim 18, wherein the viscid substance is starch or polymer.

21. (new) The dosage form as claimed in claim 18, wherein the polymer is polyarylic acid, carbomer, hydroxyethyl cellulose, chitosan, hydroxypropyl cellulose, hydroxypropyl methylcellulose, sodium carboxymethylcellulose, polyvinyl alcohol or a mixture thereof.

22. (new) The dosage form as claimed in claim 18 in the form of a gel.

23. (new) The dosage form as claimed in claim 18, wherein the gel comprises by weight based on the total weight of the gel 0.05% arsenic trioxide; 1.5% carbomer 940; 5.5% PEG; and 0.125% propyl paraben.

24. (new) The dosage form as claimed in claim 18, wherein the composition comprises arsenic trioxide in a concentration range of about 0.01 - 1 mg arsenic trioxide / g of composition.

25. (new) The dosage form as claimed in claim 24, wherein the composition comprises arsenic trioxide in a concentration range of about 0.1 - 0.5 mg arsenic trioxide / g of composition.